Lipid nanoparticles ? Metvan: reveling a novel way to deliver a vanadium compound to cancer cells

CACICEDO M.; SCIOLI S; RUIZ E; FERNANDEZ M; TORRES R; BARAN E.J; CASTRO, G.R.; LEON IE

Simposio; V11 International Simposium of Vanadium; 2018

based on chemotherapy, radiotherapy and surgery. Among chemotherapeutics, metallodrugs represent important and still promising compounds for novel cancer treatment [2]. In the last years, the uses of Vanadium complexes as antitumor agent have been gaining interest. Metvan ([VIVO(Me2phen)2(SO4)]) was identified as one of the most promising Vanadium anti-cancer compounds [3]. In this work, Metvan compound was encapsulated into well designed and developed nanostructured lipid carriers (NLCs) with the aim to improve several pharmacological properties such as bioavailability, degradation, solubility and cell up-take. A quality by design approach was performed to find the optimal nanoparticle formulation for Metvan delivery. Results exhibited that the ideal formulation was obtained by using mirystyl myristate as the lipid matrix and Pluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 ± 3.1 nm and a mean surface charge of -7.9 ± 0.8 mV. The formulation showed an encapsulation efficiency of about 80% and a sustained release of the compound was observed for more than 60 h. The mechanism of Metvan release from the nanoparticles was Korsmeyer?Peppas model, indicating that the release in significantly dependent on Metvan Fickian diffusion from the nanoparticles. On the other hand, the results showed that the nanoparticles-Metvan system are more effective than free drug to decrease cell viability on human osteosarcoma cells (MG-63), suggesting a possible different cell internalization pathway and intracellular effect.